Literature DB >> 2143351

Cardiovascular effects of intracoronary atrial natriuretic peptide administration in man.

H C Herrmann1, A D Rosenthal, C A Davis.   

Abstract

An intracoronary drug infusion protocol was employed to assess the hemodynamic effects of synthetic atrial natriuretic peptide in normal subjects and to evaluate its actions on epicardial coronary artery dimensions. Increasing concentrations of synthetic atrial natriuretic peptide (1.75 to 84 micrograms/min) were infused at a constant rate directly into the left coronary artery in eight patients with normal left ventricular function and left coronary artery angiograms. Steady-state hemodynamic parameters and high-fidelity left ventricular pressure were recorded at each dose and indexes of left ventricular contractile and diastolic function were calculated. Coronary angiograms obtained at baseline and the highest dose of atrial natriuretic peptide were compared by quantitative image analysis techniques. At the highest dose administered, atrial natriuretic peptide decreased mean pulmonary artery pressure (-36%, p less than 0.01), pulmonary capillary wedge pressure (-80%, p less than 0.01), left ventricular end-diastolic pressure (-58%, p less than 0.01), left ventricular end-systolic pressure (-11%, p less than 0.01), mean arterial pressure (-8%, p less than 0.05), and pulmonary vascular resistance (-18%, p less than 0.05). Cardiac output and systemic vascular resistance were unchanged, and heart rate and peak positive dP/dt increased. Peak negative dP/dt and the time constant of early diastolic relaxation calculated by the logarithmic method both fell at the highest dose of atrial natriuretic peptide, although the time constants calculated by other less load-sensitive methods were unchanged. Doses of intracoronary atrial peptide that did not alter left ventricular load had no effect on indexes of left ventricular systolic or diastolic function despite a presumably high intramyocardial concentration of the agent.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143351     DOI: 10.1016/0002-8703(90)90074-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

1.  Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt.

Authors:  Takahiro Kato; John Muraski; Yan Chen; Yasuyuki Tsujita; Jason Wall; Christopher C Glembotski; Erik Schaefer; Mary Beckerle; Mark A Sussman
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography.

Authors:  Z S Kyriakides; D T Kremastinos; E Bofilis; D Tousoulis; A Antoniadis; D J Webb
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

3.  Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery.

Authors:  K E Wiley; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

4.  Haemodynamic effects of atrial natriuretic peptide in hypoxic chronic obstructive pulmonary disease.

Authors:  T K Rogers; W Sheedy; J Waterhouse; P Howard; A H Morice
Journal:  Thorax       Date:  1994-03       Impact factor: 9.139

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.